Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 2Squamous Cell Carcinoma of Head and Neck 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 27Nivolumab 20atezolizumab 6Ipilimumab 6Magnetic Resonance Spectroscopy 5Specimen Handling 4Paclitaxel 4Docetaxel 4Cyclophosphamide 4Carboplatin 4fludarabine 3avelumab 3Pemetrexed 3Interleukin-2 3tislelizumab 2epacadostat 2durvalumab 2aldesleukin 2Taxes 2Radiosurgery 2Cisplatin 2veliparib 1toripalimab 1spartalizumab 1sotigalimab 1sonidegib 1sargramostim 1regorafenib 1poly ICLC 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Heavy Ion Radiotherapy × Dermatologic × Clear all
NCT05229614 2024-08-21

ICONIC

CNAO National Center of Oncological Hadrontherapy

Phase 2 Recruiting
27 enrolled
DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡